NCT03965364

Brief Summary

INITIATION is a postmarket clinical follow-up study in China. The purpose of the study is to continue to evaluate the safety and effectiveness/performance of Incraft in subjects with abdominal aortic aneurysms requiring endovascular repair in routine clinical practice. Approximately 120 subjects will be enrolled and followed through 1-years postprocedure. Up to 20 sites in China may participate.

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Aug 2019

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 15, 2019

Completed
14 days until next milestone

First Posted

Study publicly available on registry

May 29, 2019

Completed
3 months until next milestone

Study Start

First participant enrolled

August 31, 2019

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2020

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2021

Completed
Last Updated

February 26, 2021

Status Verified

February 1, 2021

Enrollment Period

1 year

First QC Date

May 15, 2019

Last Update Submit

February 24, 2021

Conditions

Outcome Measures

Primary Outcomes (1)

  • Absence of major adverse events

    MAE is defined as the combination of death, myocardial infarction, stroke/cerebrovascular accident, and renal failure.

    Within 30-days post-procedure

Secondary Outcomes (7)

  • Occurence of major adverse events

    Through 1 year post-procedure

  • Technical success

    At the conclusion of the index procedure

  • Absence of stent graft migration(>10mm)

    Assessed at 1 year

  • Absence of Type I or Type III endoleak and no aneurysm enlargement (growth >5mm)

    Assessed at 1 year compared to size measurement at 1 month

  • Absence of stent graft fracture

    Assessed within 30-days and 1-year post-procedure

  • +2 more secondary outcomes

Study Arms (1)

INCRAFT

Endovascular abdominal aortic aneurysm repair

Device: INCRAFT

Interventions

INCRAFTDEVICE

Device: Endovascular abdominal aortic aneurysm repair Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.

INCRAFT

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who are eligible for endovascular repair of an abdominal aortic aneurysm

You may qualify if:

  • Male or female aged 18 and over
  • The femoral access vessel is adequate for the selected delivery system;
  • Length of proximal aneurysmal neck ≥ 10mm;
  • Aortic neck diameter ≥ 17mm and ≤ 31mm;
  • The aortic neck is suitable for suprarenal fixation;
  • The angle of the infrarenal and suprarenal neck is ≤60 degrees;
  • Iliac fixation length ≥ 15mm;
  • Iliac diameter ≥ 7mm and ≤ 22mm;
  • Minimum total AAA treatment length (proximal landing point to distal landing point) ≥ 128mm;
  • Morphology is suitable for aneurysm repair;
  • Written informed consent form shall be provided prior to initiating any study protocol;
  • The subject is willing to follow the prescribed follow-up schedule.

You may not qualify if:

  • The subject has one of the following conditions:
  • Aneurysm sac rupture or leaking abdominal aortic aneurysm
  • Mycotic, dissecting, or inflammatory abdominal aortic aneurysm;
  • Known to be allergic or intolerant to nickel titanium (Nitinol), polyethylene terephthalate (PET) or polytetrafluoroethylene (PTFE);
  • Known contraindication to undergoing angiography or anticoagulation
  • Existing AAA surgical graft and/or a AAA stent-graft system;
  • Women of child bearing potential whom are pregnant, lactating, or planning to become pregnant during the course of the trial;

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Beijing Anzhen Hospital

Beijing, China

Location

MeSH Terms

Conditions

Aortic Aneurysm, Abdominal

Condition Hierarchy (Ancestors)

Aortic AneurysmAneurysmVascular DiseasesCardiovascular DiseasesAortic Diseases

Study Officials

  • Zhong Chen, Doctor

    Beijing Anzhen Hospital

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Target Duration
1 Year
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 15, 2019

First Posted

May 29, 2019

Study Start

August 31, 2019

Primary Completion

August 31, 2020

Study Completion

December 31, 2021

Last Updated

February 26, 2021

Record last verified: 2021-02

Locations